ERBB2 and neoplasm: An increase in number of T-cells infiltrating the tumor is associated with better patient outcome when treated with chemotherapy only (Denkert et al., 2018), chemotherapy with immunotherapies (Li et al., 2021a) as well as in combination with anti-HER2 targeted therapies, such as Trastuzumab (Loi et al., 2014).